Q-omics provides the consensus-scored GXYLT1P5 profile across patient tissues and cancer cell-line models. GXYLT1P5 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, GXYLT1P5 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, GXYLT1P5 RNA expression shows 6,888 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, KIRC, and TGCT as cancer lineages where GXYLT1P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GXYLT1P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GXYLT1P5 survival associations across molecular data types. GXYLT1P5 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GXYLT1P5 RNA expression–survival associations across cancer types. High GXYLT1P5 expression shows unfavorable associations in DLBC, THYM, KICH and COAD, but favorable associations in ESCA and KIRC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify DLBC as the clearest survival context for GXYLT1P5 RNA expression.
This table summarizes GXYLT1P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GXYLT1P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GXYLT1P5 shows lower tumor expression in HNSC, UCEC, BRCA and LUAD and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher GXYLT1P5 RNA expression in tumor versus normal tissue (log2 FC = +0.126, t-test p < 0.001).
This table shows molecular features associated with GXYLT1P5 in patient tissues and cancer cell lines. In patient samples, GXYLT1P5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
